TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions.
Brief Summary: The purpose of this multi-center study is to determine the efficacy and safety of Mucograft® in combination with the coronally advanced flap (CAF) for the treatment of gingival recessions. It is assumed that the CAF combined with Mucograft® will result in improved outcome in terms percentage of root coverage and soft tissue thickness in comparison to CAF alone (control).


Options:
A: Arm Label: test and control; Type: EXPERIMENTAL; Interventions: Procedure: Periodontal surgery to gingival recessions | Intervention Type: PROCEDURE; Name: Periodontal surgery to gingival recessions; Assigned to Arm(s): test and control
B: Arm Label: Connective tissue graft (CTG); Type: SHAM_COMPARATOR; Interventions: Procedure: Connective tissue graft | Arm Label: Connective tissue graft plus laser (CTG+L); Type: EXPERIMENTAL; Interventions: Procedure: Connective tissue graft | Intervention Type: PROCEDURE; Name: Connective tissue graft; Assigned to Arm(s): Connective tissue graft (CTG), Connective tissue graft plus laser (CTG+L)
C: Arm Label: CAF plus connective tissue graft; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CAF plus connective tissue graft, Drug: Sodium dipyrone, Drug: chlorhexidine rinse | Arm Label: Tunnel plus connective tissue graft; Type: EXPERIMENTAL; Interventions: Procedure: Tunnel plus connective tissue graft, Drug: Sodium dipyrone, Drug: chlorhexidine rinse | Intervention Type: PROCEDURE; Name: CAF plus connective tissue graft; Assigned to Arm(s): CAF plus connective tissue graft | Intervention Type: PROCEDURE; Name: Tunnel plus connective tissue graft; Assigned to Arm(s): Tunnel plus connective tissue graft | Intervention Type: DRUG; Name: Sodium dipyrone; Assigned to Arm(s): CAF plus connective tissue graft, Tunnel plus connective tissue graft | Intervention Type: DRUG; Name: chlorhexidine rinse; Assigned to Arm(s): CAF plus connective tissue graft, Tunnel plus connective tissue graft
D: Arm Label: Mucograft + CAF; Type: EXPERIMENTAL; Interventions: Device: Mucograft | Arm Label: CAF; Type: EXPERIMENTAL; Interventions: Procedure: Coronally advanced flap (CAF) | Intervention Type: DEVICE; Name: Mucograft; Assigned to Arm(s): Mucograft + CAF | Intervention Type: PROCEDURE; Name: Coronally advanced flap (CAF); Assigned to Arm(s): CAF

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Adherence Intervention After ACS Hospitalization
Brief Summary: We propose to test the effectiveness of a multi-faceted patient-centered adherence intervention among veterans following ACS hospitalization to improve adherence to cardioprotective medications (primary aim). Secondary aims will assess whether the intervention improves achievement of secondary prevention blood pressure (BP) and low density lipoprotein (LDL)-cholesterol goals, reduces cardiac endpoints (myocardial infarction ) MI hospitalization, coronary revascularization, all-cause mortality) and is cost-effective.

ANTICIPATED IMPACT(S) : If successful, the proposed intervention will increase adherence to cardioprotective medications (i.e., -blockers, statins, clopidogrel, and ACE inhibitors) by helping veterans take their medications routinely as prescribed, the quality of cardiovascular care for veterans by helping patients achieve BP and LDL goals which have been associated with improved outcomes, and the efficiency of care by using telephone calls and tele-monitoring for communication with patients rather than clinic visits. The findings of the study will address an important gap in knowledge (i.e., how to improve adherence to medications following ACS discharge) and will be generalizable to other VA Medical Centers and veterans.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Intervention Type: BEHAVIORAL; Name: Health Literacy-Focused High Blood Pressure Intervention; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: Early hospital discharge facilitated by close nurse practitioner follow-up; Assigned to Arm(s): N/A
C: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: basic intervention; Type: SHAM_COMPARATOR; Interventions: Other: basic intervention | Arm Label: extended intervention; Type: SHAM_COMPARATOR; Interventions: Other: extended intervention | Intervention Type: OTHER; Name: basic intervention; Assigned to Arm(s): basic intervention | Intervention Type: OTHER; Name: extended intervention; Assigned to Arm(s): extended intervention
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Adherence Intervention After ACS Hospitalization
Brief Summary: We propose to test the effectiveness of a multi-faceted patient-centered adherence intervention among veterans following ACS hospitalization to improve adherence to cardioprotective medications (primary aim). Secondary aims will assess whether the intervention improves achievement of secondary prevention blood pressure (BP) and low density lipoprotein (LDL)-cholesterol goals, reduces cardiac endpoints (myocardial infarction ) MI hospitalization, coronary revascularization, all-cause mortality) and is cost-effective.

ANTICIPATED IMPACT(S) : If successful, the proposed intervention will increase adherence to cardioprotective medications (i.e., -blockers, statins, clopidogrel, and ACE inhibitors) by helping veterans take their medications routinely as prescribed, the quality of cardiovascular care for veterans by helping patients achieve BP and LDL goals which have been associated with improved outcomes, and the efficiency of care by using telephone calls and tele-monitoring for communication with patients rather than clinic visits. The findings of the study will address an important gap in knowledge (i.e., how to improve adherence to medications following ACS discharge) and will be generalizable to other VA Medical Centers and veterans.


Options:
A: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Blood Pressure Monitoring Group; Type: EXPERIMENTAL; Interventions: Behavioral: Home Blood Pressure Monitoring | Intervention Type: BEHAVIORAL; Name: Home Blood Pressure Monitoring; Assigned to Arm(s): Home Blood Pressure Monitoring Group
D: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: knowledge transfer tool | Arm Label: Wait-list group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: knowledge transfer tool; Assigned to Arm(s): Educational intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Adherence Intervention After ACS Hospitalization
Brief Summary: We propose to test the effectiveness of a multi-faceted patient-centered adherence intervention among veterans following ACS hospitalization to improve adherence to cardioprotective medications (primary aim). Secondary aims will assess whether the intervention improves achievement of secondary prevention blood pressure (BP) and low density lipoprotein (LDL)-cholesterol goals, reduces cardiac endpoints (myocardial infarction ) MI hospitalization, coronary revascularization, all-cause mortality) and is cost-effective.

ANTICIPATED IMPACT(S) : If successful, the proposed intervention will increase adherence to cardioprotective medications (i.e., -blockers, statins, clopidogrel, and ACE inhibitors) by helping veterans take their medications routinely as prescribed, the quality of cardiovascular care for veterans by helping patients achieve BP and LDL goals which have been associated with improved outcomes, and the efficiency of care by using telephone calls and tele-monitoring for communication with patients rather than clinic visits. The findings of the study will address an important gap in knowledge (i.e., how to improve adherence to medications following ACS discharge) and will be generalizable to other VA Medical Centers and veterans.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
B: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A
C: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
D: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Adherence Intervention After ACS Hospitalization
Brief Summary: We propose to test the effectiveness of a multi-faceted patient-centered adherence intervention among veterans following ACS hospitalization to improve adherence to cardioprotective medications (primary aim). Secondary aims will assess whether the intervention improves achievement of secondary prevention blood pressure (BP) and low density lipoprotein (LDL)-cholesterol goals, reduces cardiac endpoints (myocardial infarction ) MI hospitalization, coronary revascularization, all-cause mortality) and is cost-effective.

ANTICIPATED IMPACT(S) : If successful, the proposed intervention will increase adherence to cardioprotective medications (i.e., -blockers, statins, clopidogrel, and ACE inhibitors) by helping veterans take their medications routinely as prescribed, the quality of cardiovascular care for veterans by helping patients achieve BP and LDL goals which have been associated with improved outcomes, and the efficiency of care by using telephone calls and tele-monitoring for communication with patients rather than clinic visits. The findings of the study will address an important gap in knowledge (i.e., how to improve adherence to medications following ACS discharge) and will be generalizable to other VA Medical Centers and veterans.


Options:
A: Intervention Type: BEHAVIORAL; Name: QuitLink (office support system for quit line referral); Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
C: Arm Label: social cognitive theory; Type: EXPERIMENTAL; Interventions: Behavioral: Social Cognitive Theory | Arm Label: Goal Systems Theory; Type: EXPERIMENTAL; Interventions: Behavioral: goal system theory | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Social Cognitive Theory; Assigned to Arm(s): social cognitive theory | Intervention Type: BEHAVIORAL; Name: goal system theory; Assigned to Arm(s): Goal Systems Theory
D: Arm Label: Automated Phone-Based Refill Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Phone-Based Refill Reminders | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Automated Phone-Based Refill Reminders; Assigned to Arm(s): Automated Phone-Based Refill Reminders

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-Centered Adherence Intervention After ACS Hospitalization
Brief Summary: We propose to test the effectiveness of a multi-faceted patient-centered adherence intervention among veterans following ACS hospitalization to improve adherence to cardioprotective medications (primary aim). Secondary aims will assess whether the intervention improves achievement of secondary prevention blood pressure (BP) and low density lipoprotein (LDL)-cholesterol goals, reduces cardiac endpoints (myocardial infarction ) MI hospitalization, coronary revascularization, all-cause mortality) and is cost-effective.

ANTICIPATED IMPACT(S) : If successful, the proposed intervention will increase adherence to cardioprotective medications (i.e., -blockers, statins, clopidogrel, and ACE inhibitors) by helping veterans take their medications routinely as prescribed, the quality of cardiovascular care for veterans by helping patients achieve BP and LDL goals which have been associated with improved outcomes, and the efficiency of care by using telephone calls and tele-monitoring for communication with patients rather than clinic visits. The findings of the study will address an important gap in knowledge (i.e., how to improve adherence to medications following ACS discharge) and will be generalizable to other VA Medical Centers and veterans.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention
B: Arm Label: Shed-Meds: A Patient-Centered Deprescribing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Shed-Meds: A Patient-Centered Deprescribing Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shed-Meds: A Patient-Centered Deprescribing Intervention; Assigned to Arm(s): Shed-Meds: A Patient-Centered Deprescribing Intervention
C: Arm Label: Pharmaceutical care program; Type: EXPERIMENTAL; Interventions: Other: Pharmaceutical Care Program | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: Pharmaceutical Care Program; Assigned to Arm(s): Pharmaceutical care program | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.
Brief Summary: This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
B: Arm Label: Doublet; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cabozantinib | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Triplet; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Monotherapy | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Triplet
C: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib, Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cabozantinib-matched placebo | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Experimental Arm | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: DRUG; Name: Cabozantinib-matched placebo; Assigned to Arm(s): Control Arm
D: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Brief Summary: The purpose of this study is to determine whether the safety, tolerability and pharmacodynamics of SB656933 in patients that have cystic fibrosis


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: KB001 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: KB001; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: AquADEKs-2; Type: EXPERIMENTAL; Interventions: Drug: AquADEKs-2, Dietary Supplement: control multivitamin | Arm Label: Control multivitamin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: control multivitamin | Intervention Type: DRUG; Name: AquADEKs-2; Assigned to Arm(s): AquADEKs-2 | Intervention Type: DIETARY_SUPPLEMENT; Name: control multivitamin; Assigned to Arm(s): AquADEKs-2, Control multivitamin
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: SB656933 | Arm Label: Treatment B; Type: EXPERIMENTAL; Interventions: Drug: SB656933 | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SB656933; Assigned to Arm(s): Treatment A | Intervention Type: DRUG; Name: SB656933; Assigned to Arm(s): Treatment B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Surgical Ablation Versus No Surgical Ablation for Patients With Persistent or Longstanding Persistent Atrial Fibrillation (AF) Undergoing Mitral Valve Surgery
Brief Summary: The purpose of the research is to determine whether treating atrial fibrillation with surgical ablation during scheduled mitral valve surgery is better than mitral valve surgery by itself without the surgical ablation. Surgical ablation of atrial fibrillation is a technique used by surgeons to deaden atrial heart tissue and block electrical signals that may be causing your heart to beat irregularly. There are no new procedures being tested in this study; both mitral valve surgery and surgical ablation are used regularly in patients who have mitral valve problems and atrial fibrillation, although no surgical ablation devices have been approved by the Food and Drug Administration for the treatment of atrial fibrillation. What is not known with certainty, is whether patients with atrial fibrillation who are having planned mitral valve surgery would do better if they also had surgical ablation rather than medication alone to treat their atrial fibrillation.


Options:
A: Arm Label: left atrial RF ablation groups; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Bi-atrial radiofrequency ablation group; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Amiodarone group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cardioblate® Surgical Ablation System; Assigned to Arm(s): Bi-atrial radiofrequency ablation group, left atrial RF ablation groups
B: Arm Label: Add-on arrhythmia surgery; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation using microwave energy | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation using microwave energy; Assigned to Arm(s): Add-on arrhythmia surgery
C: Intervention Type: DEVICE; Name: Radiofrequency ablation; Assigned to Arm(s): N/A
D: Arm Label: MVS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: MVS | Arm Label: Ablation; Type: EXPERIMENTAL; Interventions: Procedure: MVS, Device: Ablation | Intervention Type: PROCEDURE; Name: MVS; Assigned to Arm(s): Ablation, MVS | Intervention Type: DEVICE; Name: Ablation; Assigned to Arm(s): Ablation

Answer: D